Vericel Corporation (NASDAQ:VCEL) stock rose Tuesday following the company’s announcement of preliminary financial results for the fourth quarter and full year ended December 31, 2025.
The stock is gaining traction as the broader market is experiencing a mixed day, with major indices like the S&P 500 and Nasdaq slightly down.
VCEL Expects $276 Million Revenue in 2025, Profitability Continues
Vericel reported that total net revenue for 2025 is expected to be approximately $276 million, with MACI net revenue of $239.5 million, representing a 23% growth in the fourth quarter. Additionally, the company anticipates achieving GAAP net income profitability for the second consecutive year, supported by a gross margin of 74%.
The company also highlighted significant operational achievements, including the highest number of MACI implants and trained surgeons in any quarter since the product’s launch. With over 900 MACI-trained surgeons and plans to begin commercial manufacturing in a new facility in 2026, Vericel is poised for continued growth.
Vericel ended the period with about $200 million …